Abbvie Shire Merger falling through?

Quote

Anonymous

Guest
With new legislation making tax inversion less attractive will the merger fall through? From Barrons (July 18 2014:
"A $1.6 billion breakup fee would be paid to Shire if the acquisition isn't completed -- even if regulators block it."
 












Becareful what you wish for... sounds to me it just means more layoffs.

"The AbbVie-Shire deal may still go ahead, though AbbVie will likely lose upside from planned tax savings. AbbVie has said the transaction, scheduled to close in the fourth quarter, would allow it to reduce its corporate tax rate to 13 percent from 22 percent in 2016."
 






I hear Abbvie has a neuro pipeline with no neuro division, doesn't it stand to reason that bringing a well respected neuro company into the fold could both help revenue worldwide with Shire products, and have a neuro sales force ready to go for pipeline products that make it.

Just trying to understand this deal a bit more, as I have been contacted by a recruiter for expansion opportunity.

Any real insight would be appreciated, please do not spit venom friends. Thanks in advance.
 






Anonymous said:
I hear Abbvie has a neuro pipeline with no neuro division, doesn't it stand to reason that bringing a well respected neuro company into the fold could both help revenue worldwide with Shire products, and have a neuro sales force ready to go for pipeline products that make it.

Just trying to understand this deal a bit more, as I have been contacted by a recruiter for expansion opportunity.

Any real insight would be appreciated, please do not spit venom friends. Thanks in advance.
Click to expand...

LOL at Abbvie's Nuero pipeline. In addition, Abbvie's beloved Humira is about to go generic. Look at the size of that sales force. All of which do not know what their fate will be with Abbvie. Do some research before you make the jump. Recruiters are not being very truthful.
 






Anonymous said:
LOL at Abbvie's Nuero pipeline. In addition, Abbvie's beloved Humira is about to go generic. Look at the size of that sales force. All of which do not know what their fate will be with Abbvie. Do some research before you make the jump. Recruiters are not being very truthful.
Click to expand...

Recruiters are one step above politicians...bald face liars. They know shit about the jobs they're recruiting for. You are a piece of meat and a commission check. Many other and better ways to research a company and it's opportunities. No, I'm not going to tell you how...call your college placement dept.
 






The guy running the R&D for Neuroscience at AbbVie is so checked out. He's the DVP of the division and doesn't care. He's been updating his profile on Linked In looking to leave.
 






Oh yeah ? Checked out ? Try confident and relaxed.

DETAILED RESULTS FROM BIOGEN IDEC AND ABBVIE’S PIVOTAL PHASE 3 DECIDE STUDY FURTHER DEFINE THE EFFICACY AND SAFETY PROFILE OF ZINBRYTA™ (DACLIZUMAB HIGH-YIELD PROCESS)
Friday, September 12, 2014 7:30 am EDT
− Data Confirm ZINBRYTA™ is Superior to AVONEX® in Reducing Annualized Relapse Rate –
− First Presentation of Full DECIDE Results at ACTRIMS-ECTRIMS Meeting –
CAMBRIDGE, Mass. & NORTH CHICAGO, Ill.Today Biogen Idec (NASDAQ: BIIB) and AbbVie (NYSE: ABBV) announced the full results from the Phase 3 DECIDE clinical trial, which show ZINBRYTA™ (daclizumab high-yield process), dosed subcutaneously once a month, demonstrated a statistically significant improvement in reducing disease activity in people with relapsing-remitting multiple sclerosis (RRMS) compared to AVONEX® (interferon beta-1a).
These results are being presented at the Sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS) in Boston.
“The full results from DECIDE demonstrate that ZINBRYTA significantly improved key measures of multiple sclerosis disease activity compared to AVONEX, including reducing annualized relapse rate and new brain lesion development,” said Ludwig Kappos, M.D., chair, Department of Neurology and head, MS-Research Group, University Hospital, Basel, Switzerland, and lead investigator for DECIDE. “These results help us better understand ZINBRYTA as a potential treatment option for people with relapsing-remitting MS.”
 






OMG, seriously? Duodopa and dac. That's all they got in neuro. There is no pipeline. The 126 drug failed in Alzheimer's and they have no funding for schizophrenia for it.
 






Anonymous said:
Oh yeah ? Checked out ? Try confident and relaxed.

DETAILED RESULTS FROM BIOGEN IDEC AND ABBVIE’S PIVOTAL PHASE 3 DECIDE STUDY FURTHER DEFINE THE EFFICACY AND SAFETY PROFILE OF ZINBRYTA™ (DACLIZUMAB HIGH-YIELD PROCESS)
Friday, September 12, 2014 7:30 am EDT
− Data Confirm ZINBRYTA™ is Superior to AVONEX® in Reducing Annualized Relapse Rate –
− First Presentation of Full DECIDE Results at ACTRIMS-ECTRIMS Meeting –
CAMBRIDGE, Mass. & NORTH CHICAGO, Ill.Today Biogen Idec (NASDAQ: BIIB) and AbbVie (NYSE: ABBV) announced the full results from the Phase 3 DECIDE clinical trial, which show ZINBRYTA™ (daclizumab high-yield process), dosed subcutaneously once a month, demonstrated a statistically significant improvement in reducing disease activity in people with relapsing-remitting multiple sclerosis (RRMS) compared to AVONEX® (interferon beta-1a).
These results are being presented at the Sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS) in Boston.
“The full results from DECIDE demonstrate that ZINBRYTA significantly improved key measures of multiple sclerosis disease activity compared to AVONEX, including reducing annualized relapse rate and new brain lesion development,” said Ludwig Kappos, M.D., chair, Department of Neurology and head, MS-Research Group, University Hospital, Basel, Switzerland, and lead investigator for DECIDE. “These results help us better understand ZINBRYTA as a potential treatment option for people with relapsing-remitting MS.”
Click to expand...

Between this and Duodopa - 2 orphan compounds. No pipeline.
 






Anonymous said:
Oh yeah ? Checked out ? Try confident and relaxed.

DETAILED RESULTS FROM BIOGEN IDEC AND ABBVIE’S PIVOTAL PHASE 3 DECIDE STUDY FURTHER DEFINE THE EFFICACY AND SAFETY PROFILE OF ZINBRYTA™ (DACLIZUMAB HIGH-YIELD PROCESS)
Friday, September 12, 2014 7:30 am EDT
− Data Confirm ZINBRYTA™ is Superior to AVONEX® in Reducing Annualized Relapse Rate –
− First Presentation of Full DECIDE Results at ACTRIMS-ECTRIMS Meeting –
CAMBRIDGE, Mass. & NORTH CHICAGO, Ill.Today Biogen Idec (NASDAQ: BIIB) and AbbVie (NYSE: ABBV) announced the full results from the Phase 3 DECIDE clinical trial, which show ZINBRYTA™ (daclizumab high-yield process), dosed subcutaneously once a month, demonstrated a statistically significant improvement in reducing disease activity in people with relapsing-remitting multiple sclerosis (RRMS) compared to AVONEX® (interferon beta-1a).
These results are being presented at the Sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS) in Boston.
“The full results from DECIDE demonstrate that ZINBRYTA significantly improved key measures of multiple sclerosis disease activity compared to AVONEX, including reducing annualized relapse rate and new brain lesion development,” said Ludwig Kappos, M.D., chair, Department of Neurology and head, MS-Research Group, University Hospital, Basel, Switzerland, and lead investigator for DECIDE. “These results help us better understand ZINBRYTA as a potential treatment option for people with relapsing-remitting MS.”
Click to expand...

Doug F. is a tool. Please...
 
























Does this mean I won't get a package? I've been so inspired by looking for work and the packages the execs negotiated for themselves. Man, I am so incented to work for these clowns now!!!
 


















Anonymous said:
Hooray now we just need to get rid of FO and the other board members who sold us out all while lining up to collect million $$$ bonuses for themselves
Click to expand...

Well, it's clear that Ireland didn't want the Shabbieass deal to go through, either. You lucky people have been saved from those evil puppetmasters. Thank you Dick Durbin and thank you, my lucky leprecaun for shutting this Shabbieass white collar scam down. Everyday,the Shabbvie news gets better 'n better. Karma has come a'calling.

http://lat.ms/ZsO51h
 


















Top Bottom
Back
Quote